Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.76 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | KRAS | P01116 | 4/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.57 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HINT1 | P49773 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.57 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397556 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14293772 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14293912 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL29456758 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL24496886 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL9438541 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL25319857 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14268500 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL30646155 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL29359526 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-118459756-A | Temperature-sensitive material, glycoconjugate, synthesis method thereof and application of glycoconjugate in sugar solid phase synthesis | 南京师范大学 | 2024-08-09 | — | — | CN | disclosed |
| EP-4203717-A1 | CONSUMABLE | Nicoventures Trading Limited (GB) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022043666-A1 | CONSUMABLE | Nicoventures Trading Limited (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-20130045933-A1 | ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-02-21 | — | — | US | disclosed |
| WO-2011089602-A2 | ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-07-28 | — | — | WO | disclosed |
| US-5939290-A | Modified sialyl Lewisx compounds | ALBERTA RESEARCH COUNCIL (CA) | 1999-08-17 | — | — | US | disclosed |
| US-5882901-A | SIALYLATING SPECIFIED OLIGOSACCHARIDE WITH SIALYLTRANSFERASE, FUCOSYLATING WITH FUCOSYLTRANSFERASE | ALBERTA RESEARCH COUNCIL (CA) | 1999-03-16 | — | — | US | disclosed |
| US-5872096-A | MODULATION OF A CELL MEDIATED IMMUNE RESPONSE, USED TO PREPARE ARTIFICIAL ANTIGENS FOR THE GENERATION OF MONOCLONAL OR POLYCLONAL ANTIBODIES | ALBERTA RESEARCH COUNCIL (CA) | 1999-02-16 | — | — | US | disclosed |
| US-5759993-A | OLIGOSACCHARIDES AS IMMUNOMODULATORS | ALBERTA RESEARCH COUNCIL (CA) | 1998-06-02 | — | — | US | disclosed |
| US-5646123-A | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen | ALBERTA RESEARCH COUNCIL (CA) | 1997-07-08 | — | — | US | disclosed |
| US-5580858-A | Immunosuppressive and tolerogenic modified Lewisx compounds | ALBERTA RESEARCH COUNCIL (CA) | 1996-12-03 | — | — | US | disclosed |
| WO-1993024505-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045933-A1 | ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER | GALE, SLC1A5, ABCC1 | FUT5 24/4885TGM2 1672/4885KRAS 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.